---
type: paper
biblio_id: 10.1097/MCO.0000000000000353
author: Carlos
title: '"Resolving inflammation by using nutrition therapy" de Lucy V. Norlinga, Lucy Ly, and Jesmond Dalli (2017)'
subtitle: Resumen
date: 2024-09-08
---

# Síntesis

The biological actions of these novel mediators (SPMs), in controlling inflammation are distinct to current therapeutics. 

Whereas drugs in clinical use are designed to inhibit inflammation and block leukocytic recruitment, SPMs act by counter-regulating the production of proinflammatory mediators (cytokines, chemokines, and inflammatory eicosanoids), limiting leukocytic infiltration and promoting leukocyte phenotype switch. Therefore, these molecules do not prevent inflammation, but rather avert it from becoming uncontrolled and thus promote its termination. In addition, recent studies demonstrate that they actively promote tissue repair and regeneration in the context of infection.

- SPMs are essential fatty acid (EFA)-derived lipoxins, resolvins, protectins, and maresins
- EFA (Essential Fatty Acids), o ácidos grasos esenciales, son grasas que el cuerpo humano no puede sintetizar y que deben obtenerse a través de la dieta. Los dos principales tipos de EFA son el ácido linoleico (omega-6) y el ácido alfa-linolénico (omega-3)
- SPMs are produced via stereoselective enzymatic conversion of EFAs.
- EFA supplementation is associated with increased SPM and improved outcomes in experimental systems and humans.

In order to ensure that this potential is fulfilled, future clinical studies assessing the clinical utility of EFA supplementation in regulating processes within inflammation need to take into consideration several factors. These include obtaining empirical evidence for the doses to be used, identifying the optimal supplement composition (including ratios of essential fatty acids, and also other components present) and the form of the EFA that is being utilized (i.e. methylester, ethylester, triglycerides, etc.) since this will influence their bioavailability and pharmacodynamics.

## Resultados en ensayos clínicos con animales
- Dietas altas en grasas, ricas en w3 (frente a ricas en grasas saturadas), han demostrado en modelos animales una mejor protección y menor mortandad en caso de infecciones bacterianas y víricas.
- Dietas altas en w3 también protegen contra obesity, fasting hyperglycemia, glucose intolerance, and adipose tissue inflammation y, por tanton, contra el desarrollo de diabetes y síndorme metabólico.
- La suplementación de RvD1 parece mejorar neuropatías.
- También son cardioprotectoras y neuroprotectoras

## Resultados en esnsayos clinicos con humanos
- **Neuroprotección**: w3 increased monocyte phagocytosis of amyloid-beta (Ab). However, cognitive benefits remain to be tested in a clinical trial. Alzheimer’s disease is associated with brain inflammation and reduced levels of SPMs.
- **Síndrome metabólico** (which is associated with chronic low-grade inflammation): w-3 EFA supplementation (2.4 g/day for 4 weeks with aspirin 300 mg/day during the past 7 days) incrementa los niveles en sangre de SPMs (18-HEPE, 17-
HDHA y 14-HDHA). w-3 EFAs may also reduce lowgrade inflammation associated with obesity. 1.8 g/day of eicosapentaenoic acid and docosahexaenoic acid for 3 months showed a significant decrease in inflammatory markers including monocyte chemoattractant protein-1, and high sensitivity C-reactive protein, fasting triglycerides, and insulin. This corre- lated with increased plasma levels of resolvins and an up-regulation of the resolvin D1 receptor
- w-3 DPA supplementation (7 days) in healthy volunteers increased plasma resolvin D5 n-3 DPA (7S,17S-dihydroxy-8E,10Z,13Z, 15E,19Z docosapentaenoic acid and maresin 1), compared with volunteers given EPA or placebo (olive oil)


# Notas
- Fat-1 transgenic mice express the Caenorhabditis elegans (C. elegans) enzyme that converts w6 into w3 EFA.
- Parece que la dosis de w3 recomendable es aprox. 2g/dia + aspirina (dosis)
- DPA (ácido docosapentaenoico) es + importante para la inflamación que EPA (ácido eicosapentaenoico); no se dice nada de DHA (ácido docosahexaenoico) ni ALA (ácido alfalinoleico).
- El Omega-3 DPA se encuentra en grandes cantidades en la leche materna, el aceite de foca y el aceite de salmón. En la leche materna encontramos  cantidades tan grandes de DPA como DHA, y muy poco de la EPA. 






